tinidazole has been researched along with Curling Ulcer in 44 studies
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.
tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 9.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 9.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 5.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 5.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| "To determine the value of Helicobacter pylori (Hp) serology in diagnosis of active Hp infection in patients with documented duodenal ulcer (DU) and to directly compare the efficacy and side-effects profiles of metronidazole or tinidazole in a triple therapy regimen to eradicate active Hp infection." | 5.10 | Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community. ( Abbas, AB; Abbas, SZ; Crawshaw, A; Dalton, HR; English, J; McGovern, D; Shaw, S; Vivian, G, 2003) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| " pylori-positive patients with endoscopically defined peptic ulcer [DU (n = 65), GU (n = 12)] or non-ulcer dyspepsia (NUD, n = 43) were randomized to receive a 1-week course of twice daily omeprazole 20 mg, clarithromycin 250 mg and either metronidazole 400 mg (OCM) or tinidazole 500 mg (OCT) in a double-blind fashion." | 5.09 | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. ( Goddard, AF; Lawes, S; Logan, RP; Spiller, RC, 1999) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "Forty-three patients with active duodenal ulcers diagnosed at endoscopy were enrolled to receive either 1 g of sucralfate four times daily for 30 days, 500 mg of tetracycline four times daily, and 500 mg of tinidazol three times daily, for 10 days (group A; n = 23) or 150 mg of ranitidine twice daily for 30 days (group B; n = 20)." | 5.07 | Triple therapy with sucralfate is not effective in eradicating Helicobacter pylori and does not reduce duodenal ulcer relapse rates. ( De Nucci, G; Ferraz, JG; Magalhães, AF; Pedrazzoli, J; Trevisan, M, 1994) |
| "Thirty two patients with Helicobacter pylori positive duodenal ulcers resistant to treatment were randomly assigned to 4 weeks' treatment with sucralphate 4 g/day or colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14." | 5.07 | Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. ( Bianchi Porro, G; Lazzaroni, M; Parente, F, 1993) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " Although the dosage of omeprazole in pediatric patients has not been established (no pediatric formulation exists), clarithromycin is available for use in pediatric patients." | 2.40 | Guidelines for the treatment of Helicobacter pylori in the pediatric population. ( Abdel-Rahman, SM; Nahata, MC; Robinson, DM, 1997) |
| "pylori gastritis is equally prevalent in symptomatic and asymptomatic children (31 and 27." | 1.29 | Helicobacter pylori-associated gastritis in Kuwait: endoscopy-based study in symptomatic and asymptomatic children. ( al Nakib, B; Kalaoui, M; Patric, J; Radhakrishnan, S, 1993) |
| "To verify the effectiveness and side-effect profile of an eradicating regimen consisting of omeprazole 20 mg daily for 4 weeks and, during the first week, combination antimicrobial treatment with tinidazole 500 mg b." | 1.29 | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. ( Carli, G; Dalla Libera, M; Gamberini, S; Gullini, S; Merighi, A; Pazzi, P; Scagliarini, R, 1996) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.09) | 18.7374 |
| 1990's | 23 (52.27) | 18.2507 |
| 2000's | 14 (31.82) | 29.6817 |
| 2010's | 3 (6.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, CC | 1 |
| Chien, NH | 1 |
| Lee, CL | 1 |
| Yang, YC | 1 |
| Hung, CS | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Choi, HS | 1 |
| Chun, HJ | 1 |
| Park, SH | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| Teli, F | 1 |
| Khan, BA | 1 |
| Yattoo, GN | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Shoukat, A | 1 |
| Saif, R | 1 |
| Tsimmerman, IaS | 1 |
| Mikhaleva, EN | 1 |
| Marzio, L | 1 |
| Cellini, L | 1 |
| Angelucci, D | 1 |
| Abbas, SZ | 1 |
| Abbas, AB | 1 |
| Crawshaw, A | 1 |
| Shaw, S | 1 |
| English, J | 1 |
| McGovern, D | 1 |
| Vivian, G | 1 |
| Dalton, HR | 1 |
| Kos, M | 1 |
| Zinkiewicz, K | 1 |
| Stefanek, J | 1 |
| Dabrowski, A | 1 |
| Hassan, C | 1 |
| De Francesco, V | 1 |
| Zullo, A | 1 |
| Scaccianoce, G | 1 |
| Piglionica, D | 1 |
| Ierardi, E | 1 |
| Panella, C | 1 |
| Morini, S | 1 |
| Herszényi, L | 1 |
| Chaudhary, A | 1 |
| Ahuja, V | 1 |
| Bal, CS | 1 |
| Das, B | 1 |
| Pandey, RM | 1 |
| Sharma, MP | 1 |
| Namiot, Z | 2 |
| Namiot, DB | 2 |
| Kemona, A | 2 |
| Stasiewicz, J | 2 |
| Markowski, AR | 1 |
| Jaroszewicz, W | 1 |
| Górski, J | 1 |
| Goodwin, CS | 2 |
| Marshall, BJ | 2 |
| Blackbourn, SJ | 1 |
| Warren, JR | 1 |
| Phillips, M | 2 |
| Saberi-Firoozi, M | 1 |
| Massarrat, S | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Dehbashi, N | 1 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 1 |
| Mégraud, F | 1 |
| Guerre, J | 1 |
| Elouaer-Blanc, L | 1 |
| Rune, SJ | 1 |
| Pedrazzoli, J | 1 |
| Magalhães, AF | 1 |
| Ferraz, JG | 1 |
| Trevisan, M | 1 |
| De Nucci, G | 1 |
| Radhakrishnan, S | 1 |
| al Nakib, B | 1 |
| Kalaoui, M | 1 |
| Patric, J | 1 |
| Bianchi Porro, G | 2 |
| Parente, F | 2 |
| Lazzaroni, M | 1 |
| Bazzoli, F | 1 |
| Dalla Libera, M | 1 |
| Pazzi, P | 2 |
| Carli, G | 1 |
| Gamberini, S | 2 |
| Scagliarini, R | 2 |
| Merighi, A | 1 |
| Gullini, S | 2 |
| Maconi, G | 1 |
| Bargiggia, S | 1 |
| Colombo, E | 1 |
| Sito, E | 1 |
| Konturek, PC | 1 |
| Bielański, W | 1 |
| Kwiecień, N | 1 |
| Konturek, SJ | 1 |
| Baniukiewicz, A | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 1 |
| Hahn, EG | 1 |
| Spadaccini, A | 1 |
| De Fanis, C | 1 |
| Sciampa, G | 1 |
| Masciulli, V | 1 |
| Pantaleone, U | 1 |
| Di Virgilio, M | 1 |
| Magnarini, C | 1 |
| Pizzicannella, G | 1 |
| Kawano, S | 1 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Tsuji, S | 1 |
| Moshkowitz, M | 1 |
| Konikoff, FM | 1 |
| Peled, Y | 1 |
| Brill, S | 1 |
| Hallak, A | 1 |
| Tiomny, E | 1 |
| Santo, M | 1 |
| Bujanover, Y | 1 |
| Gilat, T | 1 |
| Miehlke, S | 1 |
| Lehn, N | 1 |
| Meining, A | 1 |
| Bästlein, E | 1 |
| Mannes, GA | 1 |
| Stolte, M | 1 |
| Bayerdörffer, E | 1 |
| Robinson, DM | 1 |
| Abdel-Rahman, SM | 1 |
| Nahata, MC | 1 |
| Boixeda de Miquel, D | 1 |
| Oderda, G | 1 |
| Ponzetto, A | 1 |
| Boero, M | 1 |
| Bellis, D | 1 |
| Forni, M | 1 |
| Vaira, D | 1 |
| Ansaldi, N | 1 |
| Tucci, A | 1 |
| Poli, L | 1 |
| Paparo, GF | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 1 |
| Caletti, G | 1 |
| Matarese, V | 1 |
| Rizzo, C | 1 |
| Goddard, AF | 1 |
| Logan, RP | 1 |
| Lawes, S | 1 |
| Spiller, RC | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Luman, W | 1 |
| Ling, KL | 1 |
| Ng, HS | 1 |
| Di Mario, F | 1 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Leandro, G | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Pilotto, A | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Tafner, G | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Testoni, PA | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Fiocca, R | 1 |
| Trimboli, V | 1 |
| Pallone, F | 1 |
| Choi, IJ | 1 |
| Jung, HC | 1 |
| Choi, KW | 1 |
| Kim, JH | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Rew, JS | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Chung, IS | 1 |
| Chung, JM | 1 |
| Hong, WS | 1 |
| Morris, A | 1 |
| Lane, M | 1 |
| Hamilton, I | 1 |
| Samarasinghe, D | 1 |
| Ali, MR | 1 |
| Brown, P | 1 |
| Nicholson, G | 1 |
| Kumar, N | 2 |
| Anand, BS | 1 |
| Punjabi, ND | 1 |
| Jain, PC | 1 |
| Srivastava, S | 1 |
| Blincow, ED | 1 |
| Wilson, DH | 1 |
| Blackbourn, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for tinidazole and Curling Ulcer
| Article | Year |
|---|---|
[Eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzym | 2003 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; | 1994 |
Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer | 1997 |
28 trials available for tinidazole and Curling Ulcer
| Article | Year |
|---|---|
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dru | 2013 |
Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2003 |
Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Female; | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
Gastric acid and salivary bicarbonate. Is there a relationship in duodenal ulcer patients?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bicarbonates; Drug Therapy, Combinatio | 2004 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Triple therapy with sucralfate is not effective in eradicating Helicobacter pylori and does not reduce duodenal ulcer relapse rates.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up St | 1994 |
Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duode | 1993 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Chi-Square Distributi | 1996 |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin | 1996 |
Family treatment of symptomatic children with Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Carrier State; Child; Child, Preschool; Chronic Disease; Disease Tra | 1997 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspeps | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
One week triple therapy for Helicobacter pylori associated duodenal ulcer disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichom | 1999 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
Duodenal ulcer relapse after eradication of Helicobacter pylori.
Topics: Amoxicillin; Antacids; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicoba | 1991 |
Campylobacter pyloridis is not responsible for duodenal ulcer formation: results of a controlled therapeutic trial.
Topics: Adult; Campylobacter; Campylobacter Infections; Cimetidine; Clinical Trials as Topic; Duodenal Ulcer | 1988 |
Campylobacter pyloridis is not responsible for duodenal ulcer formation, result of a controlled therapeutic trial.
Topics: Campylobacter Infections; Clinical Trials as Topic; Duodenal Ulcer; Humans; Tinidazole | 1988 |
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
Topics: Anti-Ulcer Agents; Campylobacter; Campylobacter Infections; Cimetidine; Clinical Trials as Topic; Do | 1988 |
13 other studies available for tinidazole and Curling Ulcer
| Article | Year |
|---|---|
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
[The state of immune system and effects of current therapy and immunomodulators].
Topics: Adjuvants, Immunologic; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2003 |
Efficacy of the triple therapy: proton pomp inhibitors, amoxicillin and tynidazole in Helicobacter pylori infection treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; | 2002 |
Effect of antibacterial therapy and salivary secretion on the efficacy of Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2004 |
Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Campylobacter Infections; Cimetidi | 1989 |
Helicobacter pylori-associated gastritis in Kuwait: endoscopy-based study in symptomatic and asymptomatic children.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Amoxicillin; Biopsy; Child; Child, Preschool; Duod | 1993 |
Italian omeprazole triple therapy--a 1-week regimen.
Topics: Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter | 1996 |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
[Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1997 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |